Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
Provided By PR Newswire
Last update: Dec 16, 2024
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical significance (p<0.0001)
Read more at prnewswire.comNASDAQ:NAMS (12/17/2025, 9:31:43 AM)
34.8
+0.58 (+1.69%)
Find more stocks in the Stock Screener
